BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary A...
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: GlobeNewswire
INTENDED FOR CANADIAN AUDIENCES ONLY TORONTO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for oral, once-daily PrORLADEYO® (berotralstat), which is approved in Canada for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. “Providing access to a range of therapies and alternative drug administration methods is crucial for enabling patients to self-manage their HAE, achieve optimal health and live attack-free lives. Today’s announcement marks an important step in making ORLADEYO accessible through our publicly funded healthcare system for many people across Canada living with HAE. We appreciate the collaboration between BioCryst and the pCPA to reach this agreement to help improve the quality of life for HAE patients,” said Michelle Cooper, president of HAE Canad
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Launches ORLADEYO® (berotralstat) in Ireland [Yahoo! Finance]Yahoo! Finance
- BioCryst Launches ORLADEYO® (berotralstat) in IrelandGlobeNewswire
- BioCryst to Present at Upcoming Investor ConferencesGlobeNewswire
- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.MarketBeat
- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.MarketBeat
BCRX
Earnings
- 11/4/24 - In-Line
BCRX
Sec Filings
- 11/7/24 - Form SC
- 11/7/24 - Form SC
- 11/5/24 - Form 10-Q
- BCRX's page on the SEC website